Aclacinomycin A (CAS 57576-44-0)

Aclacinomycin A was originally identified as an anti-tumor drug produced by Streptomyces galilaeus. Aclacinomycin A is the first described non-peptidic inhibitor showing discrete specificity for the CTRL (chymotrypsin-like) activity of the 20S proteasome. Aclacinomycin A has no effect on cathepsin B, it stimulates trypsin activity but inhibits the activity of both chymotrypsin and calpain. The family of aclacinomycins (of which Aclarubicin is a member) consist of highly colored compounds of which 13 yellow and 7 red-colored components have been identified. Aclarubicin has been observed to act by forming a stable complex with DNA and thus interferes with the synthesis of nucleic acids. It possesses immunosuppressant, antibacterial and antiviral properties. The aglycone portion of Aclarubicin A is known as aklavinone.

References

1. T. Isoe et al. Biochim. Biophys. Acta 1992 1117 131
2. M.E. Figueirodo-Pereira et al. J. Biol. Chem. 1996 271 16455
3. Jensen PB, Jensen PS, Demant EJ, et al. (October 1991). "Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II". Cancer Res. 51 (19): 5093–9. PMID1655244
4. Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J (2013). "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". Nature Communications. 4: 1908. doi:10.1038/ncomms2921. PMC3674280. PMID23715267